Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438007 | 0.75 | CYP2A6 (0.31) | ADORA2AADORA1 | |
| SCHEMBL29559945 | 0.75 | DYRK1A (0.39) | DYRK1AADORA2AADORA1 | |
| SCHEMBL6457654 | 0.75 | DYRK1A (0.39) | DYRK1AADORA2AADORA1 | |
| SCHEMBL20631786 | 0.71 | MPO (0.30) | — | |
| SCHEMBL30460682 | 0.69 | MAPT (0.37) | ADORA2AADORA1MEN1MAPTKMT2A | |
| SCHEMBL29900075 | 0.68 | MEN1 (0.35) | ADORA2AADORA1MEN1MAPTKMT2A | |
| SCHEMBL661049 | 0.68 | AXL (0.44) | AXLMKNK1MKNK2DYRK1AADORA2A | |
| SCHEMBL660369 | 0.68 | AXL (0.48) | AXLMKNK1MKNK2DYRK1AADORA2A | |
| SCHEMBL31155244 | 0.68 | AXL (0.44) | AXLMKNK1MKNK2DYRK1AADORA2A | |
| SCHEMBL29377266 | 0.68 | AXL (0.48) | AXLMKNK1MKNK2DYRK1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119233820-A | Azo compounds for the treatment of fibrotic diseases | 乔治-奥古斯特-哥廷根公法基金会大学的大学医学院 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024227701-A1 | PYRIDAZINE COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Tietze Chemical Consulting UG (haftungsbeschränkt) (DE) | 2024-11-07 | — | — | WO | disclosed |
| EP-4458358-A1 | PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY | Tietze Chemical Consulting UG (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4404931-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| EP-4279074-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-5013731-A | Bactericides | ICI PHARMA (FR) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | AXL 4117/4885MKNK1 3459/4885MKNK2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.